ResMed CDI (ASX: RMD) shares have been on a downward trajectory in 2026, with a 20.18% decline since the start of the year. This prompts the question: Is RMD undervalued? This article delves into the financial health of ResMed, a global medical equipment company, and explores the potential value of its shares. With a focus on its Sleep and Respiratory Care business and SaaS offerings, ResMed is a leader in CPAP machines for sleep apnea treatment. The company's strong financial performance, as evidenced by its revenue growth, gross margin, and profit, is a key attraction for investors. However, a closer examination of its financial health and market position reveals a more nuanced picture.
Financial Performance and Growth
ResMed's financial prowess is evident in its revenue and profit growth. The company reported an annual revenue of $4.685 billion, with a compound annual growth rate (CAGR) of 13.6% over the last three years. This impressive growth is further underscored by a 29.1% CAGR in profit, rising from $475 million to $1.021 billion over the same period. These figures highlight ResMed's ability to generate substantial profits while maintaining a healthy growth trajectory. The gross margin of 57.4% indicates that the company's core products and services are highly profitable, even before accounting for overhead costs.
Financial Health and Stability
To assess the overall financial health of RMD, we turn to key metrics such as net debt, debt/equity ratio, and return on equity (ROE). Net debt, a measure of the company's debt position relative to its cash holdings, stands at a negative $624 million, indicating a surplus of cash over debt. This could be interpreted as a strong safety buffer or, alternatively, inefficient capital allocation. The debt/equity ratio of 18.0% suggests that ResMed has a manageable level of debt relative to its shareholder equity, implying a relatively low level of financial leverage.
The ROE of 22.7% in FY24 is another positive sign, indicating that ResMed is allocating its capital efficiently and generating significant value for shareholders. This high ROE suggests that the company is on a strong financial footing and has the potential to sustain its growth trajectory.
Market Position and Valuation
The current price-sales ratio of 4.38x is significantly lower than the 5-year average of 8.70x, indicating that RMD shares are trading below their historical average. This could be attributed to a decline in share price or an increase in sales, or a combination of both. However, it's important to note that this is just one valuation technique, and investment decisions should not be based solely on a single metric. The Rask websites offer valuable resources, including online investing courses and free valuation spreadsheets, which can provide a more comprehensive analysis using models like Discounted Cash Flow (DCF) and Dividend Discount Models (DDM).
Conclusion
In conclusion, ResMed CDI's shares present an intriguing investment opportunity. The company's strong financial performance, coupled with a healthy balance sheet and efficient capital allocation, suggests that it is well-positioned for continued growth. While the current market conditions may have contributed to the share price decline, a deeper analysis reveals a company with a solid foundation and a promising future. Investors considering RMD shares should conduct a thorough evaluation, utilizing the provided resources to gain a comprehensive understanding of the company's value proposition and potential for long-term growth.
